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Abstract
Background: While evidence suggested that the activity states of Protein kinase B (AKT/PKB) and
endothelial nitric oxide synthase (eNOS) play an important role in the progression of the Growth
Hormone (GH) signal cascade, the implication of the activation of AKT/PKB and eNOS in terms of
their function in the signaling pathway was not clear.
Results: Using a specific AKT/PKB inhibitor and a functional proteomic approach, we were able
to detect the activities of multiple signal transduction pathway elements, the downstream targets
of the AKT/PKB pathway and the modification of those responses by treatment with GH. Inhibiting
the AKT/PKB activity reduced or eliminated the activation (phosphorylation) of eNOS. We
demonstrated that the progression of the GH signal cascade is influenced by the activity status of
AKT and eNOS, wherein the suppression of AKT activity appears to augment the activity of
extracellular signal-regulated kinases 1 and 2 (Erk1/2) and to antagonize the deactivation
(phosphorylation) of cyclin-dependent kinase 2 (CDC2/Cdk1) induced by GH. Phosphorylation of
GSK3a/b (glycogen synthase kinase 3), the downstream target of AKT/PKB, was inhibited by the
AKT/PKB inhibitor. GH did not increase phosphorylation of ribosomal S6 kinase 1 (RSK1) in
normal cells but increases phosphorylation of RSK1 in cells pre-treated with the AKT and eNOS
inhibitors.
Conclusion: The MAP kinase and CDC2 kinase-dependent intracellular mechanisms are involved
in or are the targets of the GH's action processes, and these activities are probably directly or
indirectly modulated by AKT/PKB pathways. We propose that the AKT/PKB-eNOS module likely
functions as a negative feedback mediator of GH actions.
Background
Endothelial nitric oxide synthase (eNOS or NOS3) is a tar-
get downstream of activated AKT/PKB. In response to var-
ious forms of cellular stimulation, eNOS is
phosphorylated by AKT/PKB [1]. The AKT proto-onco-
gene is an important regulator of various cellular proc-
esses, including glucose metabolism and cell survival [2-
5]. AKT/PKB can be phosphorylated and activated by the
activation of receptor tyrosine kinases and the G-protein-
coupled receptor, as well as the stimulation of cells by
mechanical forces [6]. The relationships between the acti-
vation of AKT, its downstream effectors and the produc-
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tion of soluble second messengers, have been studied
extensively, and comprehensive insight into the regula-
tion and function of AKT has been gained over the past ten
years [7]. It has become increasingly evident that the
defects in AKT/PKB signaling also underlie a diverse array
of diseases. Therefore, the clarification of AKT's down-
stream targets and functions is of central importance to
our understanding and treatment of such diseases.
Exogenous growth hormone (GH) treatment has been
explored as one potential adjunct for managing the cata-
bolic processes that challenge the host response to infec-
tion stress [8,9]. Few definitive studies in cattle, if any,
have addressed NO production as affected by GH treat-
ment prior to the onset of immune challenge as well as
signal transduction pathways that involved. The effects of
GH are modulated through coordinated changes in gene
expression and/or the function of the gene products by
phosphorylation or other modifications that are the out-
come of interactions between hormone-activated signal
transduction pathways and specific feedback loops [10].
Coordinated cellular responses to GH are subsequently
modulated through a molecular cascade involving both
the activation and activation-termination of post-receptor
signal transduction element responses [11,12]. GH
actions at the cellular level can also be thought of in terms
of the reactivity of tissues changing between "GH respon-
sive" and "GH resistant" states [13,14]. These changing
states of relative GH responsiveness have come to be rec-
ognized as vital for the establishment of such diverse
attributes as the sexual dimorphic character of GH respon-
siveness [15], short-term GH-derived refractoriness [16]
and the reprioritization of GH-directed actions on metab-
olism that develops during infection [17,18].
Studies from our laboratory have suggested that the pro-
duction of nitrated protein during low-level, pro-inflam-
mation stress, is increased by GH treatment through a
direct effect on the competing activities of NOS and argi-
nase, modulating critical control points in the proinflam-
matory cascade [17]. More recently, we also demonstrated
that tyrosine residues 1007 and 1008 of Janus kinase 2
(JAK2), which are critical to the GH/cytokine receptor
phosphorylation activation of JAK2 [19], could become
nitrated [20]. This particular nitration developed in and
was co-localized to membrane caveolae and their accom-
panying content of eNOS, and the recently characterized
caveolar localization of the GH receptor [21,22].
While evidence suggested that the activity states of AKT
and eNOS play an important role in the progression of the
GH signal cascade [23-25], the implication of the activa-
tion of AKT/PKB and eNOS in terms of their function in
the signaling pathway was not clear. Our hypothesis is
that the GH-mediated activation of the AKT/PKB and
eNOS signaling module functions not only as a positive
affecter, but also as a negative feedback mediator of GH
actions, that can, with specificity, affect and coordinate
GH signal transduction processes in cells. The purpose of
the present study was to examine in vitro responses of the
potential signal transduction pathway elements of bovine
cells and the modification of this response by treatment
with recombinant GH. Using specific AKT/PKB and eNOS
inhibitors and a functional proteomic approach in vitro,
we were able to detect the activities of multiple potential
signal transduction pathway elements; the downstream
targets of AKT pathway; and the modification of those
responses by treatment with GH. Combining the data
from the in vitro experiments with the functional pro-
teomic analysis, we propose that the AKT/eNOS signaling
module may function as a feedback loop in the GH sign-
aling pathway.
Results
The AKT/PKB inhibitor effectively inhibited 
phosphorylation (activation) of AKT, and eNOS
The MDBK cell culture system was used as a model to
examine whether the function of AKT/PKB may be associ-
ated with the ability of GH to modulate the activation
state of the NO-generating enzyme eNOS. Akt (protein
kinase B), a subfamily of the AGC serine/threonine
kinases, plays critical roles in survival, proliferation, glu-
cose metabolism, and other cellular functions. Akt activa-
tion requires the recruitment of the enzyme to the plasma
membrane by interacting with membrane-bound lipid
products of phosphatidylinositol 3-kinase [26]. Mem-
brane-bound Akt is then phosphorylated at two sites for
its full activation [27]; Thr-308 in the activation loop of
the kinase domain is phosphorylated by 3-phosphoi-
nositide-dependent kinase-1 (PDK1) and Ser-473 in the
C-terminal hydrophobic motif by a putative kinase PDK2.
In order to determine whether the intracellular generation
of p-eNOS and p-AKT by GH could be localized to a given
compartment, subcellular fractionation was used. Pro-
teins were extracted from MDBK cells using the ProteoEx-
tract®  subcellular extraction kit (Calbiochem). We
preconditioned MDBK cells in media containing AKT
inhibitors for 30 min and investigated the effect of block-
ing eNOS phosphorylation after GH treatment. First, after
treatment with GH (Figure 1A), Western blots for AKT,
pThr308-AKT and p-Ser473-AKT clearly indicated that GH
increased the intensity band for p-AKT (Thr308 and
Ser473) (Figure 1A). Both pThr308-AKT and p-Ser473-
AKT increased the total amount of phosphorylation, with
pThr308 decreasing slightly in cytosol. Since AKT/PKB is
activated by phosphorylation at Thr308 and Ser473, we
can safely assume that the GH challenge stimulated AKT/
PKB activity. Most of the phosphorylated AKT was local-
ized in the nuclear fraction. Although phosphorylation of
AKT in cytosol fraction shows a slight decrease in density,
overall the trend of total phosphorylation of AKT from
three cellular fractions does not change. We suspect thatJournal of Molecular Signaling 2009, 4:1 http://www.jmolecularsignaling.com/content/4/1/1
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this discrepancy may be the result of the trans-location of
the pAKT protein after GH stimulation. We also noted that
there is a slight difference in the subcellular localization of
AKT phosphorylated at Thr308 and Ser473 (Figure 1,
panel A). This difference is consistent in replicated exper-
iments. We do not have explanation for this observation.
However, since two phosphorylation sites (Ser473 and
Thr308) are phosphorylated by two different kinases and
phosphorylation of two sites is not dependent to each
other [27], we speculate the possibility that two popula-
tions of AKT, one phosphorylated at Thr308 and the other
at Ser473 may exist. Pre-treatment of cells with AKT inhib-
itor for 30 minutes, however, eliminated the phosphor-
ylation of AKT at both sites. Moreover, in parallel, Western
blotting experiments using the same subcellular fractions
were conducted to analyze the phosphorylation of eNOS,
a membrane bound enzyme. Our data show that, after
treatment GH, eNOS phosphorylation at Ser1177 was ele-
vated 30 minutes after the GH challenge and phosphor-
ylation of eNOS at Ser1177 is AKT-dependent (Figure 2).
AKT can directly phosphorylated eNOS at Ser1177 and
activate the enzyme [1,28,29]. When cells were pre-treated
with the AKT inhibitor, the specific generation of phos-
phorylated eNOS at Ser1177 decreased to almost undetec-
table levels. Since eNOS phosphorylation by AKT could
be direct or indirect, eNOS inhibitor (1 mM NG-Monome-
thyl arginine, CalBiochem) was also used in this experi-
ment as a control to test actual eNOS dependency (Figure
2). Both phosphorylated eNOS and eNOS were localized
in the membrane fraction (Figure 2) as indicated by cave-
olin, a membrane protein marker. This is consistent with
our previous observation in vivo that phosphorylated
eNOS is caveolae-associated [30]. In addition to the local-
ization of eNOS, we also see that more than 90% of his-
tone appears in the fraction of the nucleus (Figure 1A),
and GAPDH appears only in the cytosol fraction (Figure
1A). All of these data indicated that the subcellular extrac-
tion procedure produced clean cellular fractionations.
Panel A: Cells with or without pre-treatment of AKT inhibi- tor (AKTi) were challenged with GH at 200 ng/ml for 0, 15  and 30 min respectively Figure 1
Panel A: Cells with or without pre-treatment of AKT 
inhibitor (AKTi) were challenged with GH at 200 ng/
ml for 0, 15 and 30 min respectively. Cellular proteins 
were extracted from MDBK cells using the ProteoExtract® 
subcellular extraction kit (Calbiochem) following the manu-
facturer's instructions. Western blotting experiments were 
conducted and analyzed as specified in Material and Methods. 
Panel B shows the quantitation of AKT phosphorylation (p-
Thr308) after GH treatment.
AKT inhibitor eliminates the phosphorylation of eNOS  (Ser1177) Figure 2
AKT inhibitor eliminates the phosphorylation of 
eNOS (Ser1177). MDBK cells with or without pre-treat-
ment of AKT inhibitor for 30 min were challenged with GH 
at 200 ng/ml for 0. 15 and 30 min respectively. At the indi-
cated time points, proteins were extracted from MDBK cells 
using the ProteoExtract® subcellular extraction kit (Calbio-
chem) and Western blot analyses were performed. Caveolin 
was used as a membrane protein marker. AKTi: AKT inhibi-
tor. AKTi + GH: Cells pretreated with AKT inhibitor for 30 
min before GH administration.Journal of Molecular Signaling 2009, 4:1 http://www.jmolecularsignaling.com/content/4/1/1
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The metabolic effects of GH are either chronic diabe-
togenic or acute insulin-like. After exposure to GH the
ability of the cells to respond with insulin-like effects dis-
appears within one to three hours [10,31]. We suspect
that AKT/eNOS may function as the negative feedback
loop and play an important role in GH-induced GH
desensitization. Therefore, we next performed a kinetic
experiment to assess the changes in the phosphorylation
of eNOS over the time course of GH stimulation, as well
as the response of eNOS to secondary GH stimulation.
GH was administrated at 0 min and followed with a sec-
ond treatment at 75 min to normal cultured cells and cells
preconditioned with the AKT inhibitor. The Western blot
data (Figure 3) indicated that the GH-induced phosphor-
ylation of eNOS started about 15 minutes after GH treat-
ment and the phosphorylation of eNOS was saturated at
about 75 min. In order to further investigate whether the
cells retained their sensitivity to GH at the peak of the
reaction to the first stimulation, as measured by the phos-
phorylation of eNOS, we administrated a second GH
stimulation at this time point (75 min post first GH).
Notably, the phosphorylation of eNOS levelled off after
75 minutes, and secondary stimulation with GH did not
induce further phosphorylation of eNOS; rather, the level
of eNOS phosphorylation was maintained. On the other
hand, the AKT inhibitor significantly (P < 0.01) reduced
the level of eNOS phosphorylation and therefore almost
eliminated the activation of eNOS.
Since the GH-mediated nitration of JAK2 in critical regu-
latory tyrosine-associated sites has been found to serve as
a novel regulatory post-translational modification, com-
plementary but antagonistic to phosphorylation [20,30],
we investigated the effects of the AKT and eNOS inhibitors
on the nitration of JAK-2 (nitro-JAK2) in MDBK cells with
a specific antibody for nitrated JAK2 [20]. Normal grow-
ing cells and cells pre-treated with the AKT and eNOS
inhibitors were treated with GH at 200 ng/ml. Proteins
were extracted at 0, 15, 30, 60, 90 and 120 min. Western
blots were performed with anti-nitro-JAK2. Fifteen min-
utes after treatment with GH, JAK2 was nitrated, with the
highest level observed at about 30 minutes (Figure 4). In
contrast, at both the 15 minute and the 30 minute time
points, the specific generation of the nitrated JAK2
decreased after GH when the cells were pre-treated with
either the AKT or eNOS inhibitor. Therefore, this experi-
ment and the temporal patterns of JAK2 nitration con-
firmed that both AKT and eNOS are functioning as
regulators of JAK2 nitration [17,30].
Downstream elements of cellular signal transduction 
pathways affected by GH and pre-treatment with the AKT 
inhibitor
To further investigate the roles of AKT/PKB in GH signal-
ing pathways, we utilized a global proteomics phospho-
antibody array-based approach (Kinetworks Phospho-Site
Screen (KPSS)-6.0, http://www.kinexus.ca) to analyze the
signal transduction pathways of the GH axis and the roles
of AKT/PKB in Madin-Darby bovine kidney epithelial
(MDBK) cells. Samples were prepared according to the
instruction of the service provider, and sent to the service
provider for phosphor-site screen and quantitation.
The changes in the phosphorylation of eNOS after one or  two GH challenges Figure 3
The changes in the phosphorylation of eNOS after 
one or two GH challenges. GH was administrated first at 
0 min and again time at 75 min to MDBK cell cultures with or 
without AKT inhibitor pre-treatment. Whole cell extracts 
were prepared at the time point 0, 15, 75, 90 and 150 min 
after first GH challenge. Western blots using the antibodies 
against phospho-eNOS and phospho-AKT were performed. 
Panel A: The eNOS phosphorylation after one GH challenge. 
Panel B: The eNOS phosphorylation with two GH chal-
lenges, with or without AKT inhibitor pre-treatment for 30 
min. Western blot with phospho-AKT (Thr308) was used to 
monitor the effectiveness of the AKT inhibitor. Loading con-
trol: Identical gel stained with SimplyBlue™ (Invitrogen). 
Panel C shows the quantitation of eNOS phosphorylation 
(Ser1177) after GH treatment. 1 GH: the quantitation for 
one GH challenge; 2 GH: quantitation for two GH challenge; 
AKTi + GH: AKT inhibitor pretreated for 30 min before GH 
challenge; *: First GH challenge, **: second GH challenge.Journal of Molecular Signaling 2009, 4:1 http://www.jmolecularsignaling.com/content/4/1/1
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Essentially, the entire cell lysate sample (an equal amount
of protein from each of sample) was applied in one lane
that spanned the width of the SDS-PAGE gel. A multi-
blotting apparatus that features 20 separate slot chambers
was used for incubation with multiple primary antibodies
and then secondary antibodies. The immunoblot was
incubated with an enhanced chemo-luminescence ECL-
plus reagent. The ECL signal produced on the immunob-
lot was detected using a Bio-Rad FluorS Max Multi-Imager
with a 16-bit camera and with the Bio-Rad Quantity One
software program for quantitation. The band densities
were normalized to correct for differences in the amounts
of protein. The normalized data were obtained from the
service provider. A diverse set of phospho-proteins pivotal
in a wide range of cellular regulations were identified (Fig-
ure 5A) and quantitated (Figure 5B). Remarkably, CDC2/
Cdk1 (Cell division control protein 2/Cyclin-dependent
protein kinase 1) became hyperphosphorylated (deacti-
vated) at 30 minutes after GH treatment, whereas pre-
treatment of cells with the AKT inhibitor antagonized the
deactivation of CDC2/Cdk1 induced by GH. Since the
data were normalized to correct for the differences in
amounts of protein, the quantitation reflects the relative
levels of CDC2/Cdk1 protein phosphorylation. The AKT
inhibitor antagonized the effects of GH on the stress-acti-
vated proteins kinase (cJun NH2 terminal kinase, JNK1)
and tyrosine hydroxylase (TYH), and restored the phos-
phorylation level of both proteins. Pre-treatment with the
AKT inhibitor also inhibited the phosphorylation of the
ErbB2 receptor tyrosine kinase (ErbB2) and eukaryotic
translation initiation factor 4 (elF-4E). On the other hand,
AKT inhibitor augmented the already increased activities
Both AKT and eNOS inhibitors eliminate the nitration of  JAK2 Figure 4
Both AKT and eNOS inhibitors eliminate the nitra-
tion of JAK2. GH was administrated to cell cultures with or 
without either AKT or eNOS inhibitor pre-treatment for 30 
min. Whole cell extracts were analyzed with Western blot 
using an antibody (Anti-nitro-1007-Y1008Y-JAK2). AKTi: AKT 
inhibitor, eNOSi: eNOS inhibitor. Loading control: Identical 
gel stained with SimplyBlue™ (Invitrogen).
Panel A: KPSS-6.0 phosphoantibody multi-immunoblot array;  MDBK cells were treated with or without the AKT inhibitor  for 30 minutes before GH administration Figure 5
Panel A: KPSS-6.0 phosphoantibody multi-immunob-
lot array; MDBK cells were treated with or without 
the AKT inhibitor for 30 minutes before GH adminis-
tration. The whole cell lysates were prepared after 30 min 
of GH challenge and analyzed using the KPSS-6.0 phosphoan-
tibody multi-immunoblot array by Kinexus http://www.kin-
exus.ca/KPSS.htm. The phosphor-protein targets of interest 
are indicated by arrows and abbreviations. The upper panel 
gives the array analysis of normal cells without GH (control); 
the middle panel shows the array analysis of GH treated 
cells; the lower panel gives the array analysis of the AKT 
inhibitor pretreated cells before GH administration. Panel B: 
Normalized quantitation of the results of KPSS-6.0 phos-
phoantibody multi-immunoblot array. The quantitation is the 
trace quantity of the band corrected to a scan time of 60 sec-
onds. The normalized quantitation is the quantitation nor-
malized to correct for differences in protein amounts.Journal of Molecular Signaling 2009, 4:1 http://www.jmolecularsignaling.com/content/4/1/1
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of the translation initiation factor elF2a, extracellular sig-
nal-regulated kinases Erk1 and Erk2 after GH treatment by
stimulating the additional phosphorylation of elF2a, Erk1
and Erk2. The data also showed that the AKT inhibitor
reduced the phosphorylation of AKT to lower than 40% of
the basal level. We noted that the basal levels of some pro-
teins such as ERK1/2 and AKT were substantial in this par-
ticular experiment. We suspect that this was due to the
cell's sensibility to manipulation, such as the stress of
aspirating and replacing the medium-containing vehicle
for the control cells. The substantial basal levels seem not
affecting our conclusion, however, it may decrease the
ability to detect more GH-dependent events. Therefore
appropriate precaution should be employed in future
experiments.
GH is an important endocrine and autocrine/paracrine
regulator of growth promotion and immuno-stimulation.
It controls proliferation, apoptosis, growth and differenti-
ation [32,33]. It is generally believed that GH activity
mediated by the cytosolic tyrosine kinase Janus kinase 2
(JAK2) upon GH-GH receptor interaction, resulting in
tyrosine phosphorylation of downstream targets includ-
ing MAP kinases [34]. However, the roles of these path-
ways, especially that of CDC2, are not well defined.
Therefore, it is very important to validate the data
obtained from the global proteomics phospho-antibody
array, which indicated that the AKT inhibitor prevented
the deactivation of CDC2/Cdk1 induced by GH. We stim-
ulated normal growing cells and AKT inhibitor-pre-
treated cells, and prepared sub-cellular fractions of the
cells at designated time points. The effectiveness of the
treatment with the AKT inhibitor was monitored using
anti-pAKT (Ser473) antibody (Figure 6B). The results of
Western blot using antibodies against p-(Y15)-CDC2/
Cdk1 (phosphorylated CDC2/Cdk1 at tyrosine 15) and
CDC2/Cdk1 (Figure 6) show that after GH treatment, the
phosphorylation of CDC2/Cdk1 (Y-15) accumulated,
while the total CDC2/Cdk1 decreased. However, pre-
treating cells with the AKT inhibitor reversed the course.
Total CDC2/Cdk1 increased and p-(Y15)-CDC2/Cdk1
decreased after GH stimulation. These findings are con-
sistent with the data obtained from the global proteomics
phospho-antibody array.
The MAPK/ERK pathway is a signal transduction pathway
that couples intracellular responses to the binding of
growth factors to cell surface receptors. For the same rea-
son, we further validated the ERK response to GH with or
without pre-treatment with the AKT inhibitor. First, using
the Proteome Profiler Array™-Human Phospho-MAPK
Array (see Methods), we confirmed that the AKT inhibitor
and GH have augmentative function, in inducing the
phosphorylation of Erk1/2 (Figure 7A, B). Erk1 and Erk2
regulate transcription indirectly by phosphorylating the
90 kDa ribosomal protein S6 kinases (RSKs), a family of
broadly expressed Ser/Thr kinases activated in response to
mitogenic stimuli, including growth factors and tumor-
promoting phorbol esters [35,36], Therefore, it is not
unexpected that GH would not increase phosphorylation
of RSK1 in normal cells but increases phosphorylation of
RSK1 in cells pre-treated with the AKT and eNOS inhibi-
tors.
Another important confirmation of effect of AKT/PKB
inhibitor is the significant (P < 0.01) dephosphorylation
(activation) of GSK3a/b (glycogen synthase kinase 3), the
downstream target of AKT/PKB [37], was induced by the
AKT/PKB inhibitor (Figure 7A and 7C). Dephosphoryla-
tion of GSK3a/b, however, did not significantly affected
by pre-treatment of eNOS inhibitor. These differential
effects of AKT/PKB inhibitor and eNOS inhibitor on acti-
vation of GSK3a/b are understandable because AKT/PKB
is the upstream regulator (inhibitor) of GSK3a/b [38]. In
this particular experiment, we also observed that the
eNOS inhibitor decreased the ability of GH to induce
phosphorylation of AKT. One possible explanation of this
effect is that the eNOS inhibitor decreases intracellular
NO, thereby decreasing PI-3K and subsequent down-
stream AKT activities [39,40].
We also stimulated normal growing cells and AKT inhibi-
tor-pretreated cells with GH and prepared cell extracts at
designated time points with double stimulations of GH.
We then analyzed the cell extracts by Western blot using
antibodies against Erk1/2 and p-Erk1/2. For the purpose of
comparison, the Western blots were first blotted with anti-
bodies against p-ERK. The membranes were then stripped
with Restore PLUS Western Blot Stripping Buffer (Pierce
Biotechnology, now Thermo Scientific) and re-blotted with
anti-ERK. The Western blots (Figure 8A and 8B) are quanti-
tated and presented in Figure 8C. After GH treatment, phos-
pho-Erk1/2 levels increased, peaked at about 30 to 60 min
and levelled off, suggesting that the biochemical events
associated with the initiation of the GH signal transduction
cascade did in fact occur (Figure 8A, B). However, the sec-
ond GH dosage added to the cell culture did not induce
more phosphorylation in Erk1/2 as comparison to the
phosphorylation pattern of Erk1/2 from cells with single
stimulation of GH (Figure 8B and 8C). In cells pre-treated
with the AKT inhibitor, the levels of phospho-Erk1/2
increased, peaked at much later time points, and secondary
GH enhanced the phosphorylation of Erk1/2. The phos-
phorylation of Erk1/2 in eNOS-inhibitor-pre-treated cells
shows similar patterns after GH stimulation to AKT inhibi-
tor-pre-treated cells (Figure 8A and 8C).
Discussion
Extensive research over the past decades on the wiring of
signal transduction pathways has uncovered a level of
complexity. It is clear now that individual pathways are
only small parts of fully integrated networks within theJournal of Molecular Signaling 2009, 4:1 http://www.jmolecularsignaling.com/content/4/1/1
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Phosphorylation states of CDC2 in a time course of GH treatment in the cell culture with or without AKT inhibitor (AKTi)  pre-treatment Figure 6
Phosphorylation states of CDC2 in a time course of GH treatment in the cell culture with or without AKT 
inhibitor (AKTi) pre-treatment. After treatment with GH at the indicated time points, proteins were extracted from 
MDBK cells using the ProteoExtract® subcellular extraction kit (Calbiochem). Two identical gels were transferred to nitrocel-
lulose membrane and Western blot analyses were performed for total CDC2/Cdk1 and phosphor-CDC2/Cdk1. Panel A: Tem-
poral changes of phospho-CDC2/Cdk1 (p-(Y15)-CDC2/Cdk1 and total CDC2/Cdk1 after administration of GH. Panel B: 
Temporal changes of phosphor-CDC2/Cdk1 (p-(Y15)-CDC2/Ckd1) and total CDC2/Cdk1 in AKT inhibitor (AKTi)-pretreated 
MDBK cells after administration of GH. Panel C: Quantitation of phosphor-CDC2/Cdk1 (p-(Y15)-CDC2/Cdk1) from panels A 
and B. n = 2 replicated experiments.Journal of Molecular Signaling 2009, 4:1 http://www.jmolecularsignaling.com/content/4/1/1
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Proteome Profiler Array™-Human Phospho-MAPK analysis; whole cell extracts from normal cells, and GH challenged (30 min- utes) cells, with or without pre-treatment with either AKT or eNOS inhibitors, were analyzed with Proteome Profiler  Array™-Human Phospho-MAPK Figure 7
Proteome Profiler Array™-Human Phospho-MAPK analysis; whole cell extracts from normal cells, and GH 
challenged (30 minutes) cells, with or without pre-treatment with either AKT or eNOS inhibitors, were ana-
lyzed with Proteome Profiler Array™-Human Phospho-MAPK. Panel A: Data for one representative array. Panel B: 
Quantitation of phospho-Erk1/2. Panel C: Quantitation of phospho-GSK a/b. n = 2 replicated experiments. *: P < 0.05; **: P < 
0.02.Journal of Molecular Signaling 2009, 4:1 http://www.jmolecularsignaling.com/content/4/1/1
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cell and there is no signal pathway operating in isolation
[7]. In the present study, we used an established bovine
cell line (MDBK) to determine the roles of AKT/PKB and
eNOS, as well as the downstream elements in the GH sig-
naling pathway. Using a specific AKT/PKB inhibitor and
the functional proteomic approach, we were able to detect
the activities of multiple signal transduction pathway ele-
ments, the downstream targets of the AKT/PKB pathway
and the modification of those responses by treatment
with GH. Three approaches were applied, and separate
and independent in vitro experiments were conducted to
define the potential mechanism of AKT/eNOS activities.
The pre-treatment of MDBK cells with the AKT inhibitor
prior to the addition of media containing GH resulted in
prolonged and augmented Erk1/2 phosphorylation (acti-
vation) after the GH challenge. AKT inhibitor also antag-
onizes the effects of GH, which induces deactivation
(phosphorylation) of CDC2/Cdk1. Inhibiting the AKT/
PKB activity reduced or eliminated the activation (phos-
phorylation) of eNOS. Based on these observations, we
conclude that the AKT/eNOS signaling module may func-
tion as a potential feedback loop in the GH signal path-
way.
Endothelial NOS was first identified as a substrate of AKT/
PKB [28]. Stimulation of Phosphoinositide 3-kinases
(PI3K)/AKT by shear stresses and VEGF (vascular endothe-
lial growth factor) elicits the serine phosphorylation of
eNOS, thereby enhancing enzyme activity in a Ca2+-inde-
pendent manner. The activation of eNOS by AKT contrib-
utes to the important physiological effects of AKT on
apoptosis, cell attachment and cell proliferation [41-45].
In fact, serine/threonine kinase AKT/PKB is regarded as a
central node in cell signaling downstream of the growth
factor, cytokines, and other cellular stimuli [[7] and refer-
ences wherein]. The apparent responsiveness of cells to
the single or double GH challenge was either prolonged or
augmented, assuming that the measured level of phos-
pho-eNOS and CDC2/Cdk1 is indicative of maintained
responsiveness. However, the downstream pathways of
AKT/PKB which modulate its effects are still undefined.
The results reported here indicate that AKT/PKB can mod-
ulate the effects of GH on cell growth and survival either
directly or indirectly through the MAPK- and CDC2/
Cdk1-dependent signaling cascade.
The CDC2/Cdk1 protein is a member of the Ser/Thr pro-
tein kinase family. This protein is a catalytic subunit of the
highly conserved protein kinase complex known as the M-
phase promoting factor (MPF), which is essential for the
G1/S and G2/M phase transitions of the eukaryotic cell
cycle. Mitotic cyclins stably associate with this protein and
function as regulatory subunits. As the effect of the AKT
inhibitor, CDC2 maintains its dephosphorylation (activa-
tion) status. It has been reported that CDC2/Cdk1 and
Both AKT and eNOS inhibitors prolong and augment Erk1/2  phosphorylation Figure 8
Both AKT and eNOS inhibitors prolong and augment 
Erk1/2 phosphorylation. GH was administrated first at 0 
min and a second time at 75 min to cell cultures with or 
without AKT inhibitor pre-treatment. Whole cell extracts 
were prepared. A) Western blots using an antibody against 
phospho-Erk1/2 and Erk1/2 show that the phosphorylation of 
Erk1/2 starts 15 min after the first GH administration and 2 
levels off after 75 min even with secondary GH administra-
tion. B) For comparison, cell extracts from cells with single 
GH stimulation were prepared and Western blots were per-
formed for Erk1/2 and phosphorylated Erk1/2. C) Quantita-
tion of the Western blots data. *: First GH challenge, **: 
second GH challenge. AKTi: Akt inhibitor, eNOSi: eNOS 
inhibitor.Journal of Molecular Signaling 2009, 4:1 http://www.jmolecularsignaling.com/content/4/1/1
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kinase from the tyrosine kinase family are involved in the
GH response. Inhibitors of tyrosine kinase prevented GH
effects on IGF-1 release [46] and apoptosis [47] in porcine
granulosa cells. The anti-apoptosis effect of GH on por-
cine granulosa cells can also be prevented by inhibitors of
protein kinase G and CDC2/Cdk1 kinases, suggesting that
these kinases are required for GH mediation [48]. Phos-
phorylation of CDC2/Cdk1 on Thr14 (mainly by Myt1
kinase) and Tyr15 (mainly by Wee 1 kinase) inhibits its
activity during the G2 phase of the cell cycle, presumably
through a direct effect on the phosphotransfer activity,
while dephosphorylation of CDC2/Cdk1 on both sites by
the phosphatase (CDC25) of CDC2/Cdk1 de-inhibits
CDC2/Cdk1 during early mitosis [49]. The regulation of
the spatiotemporal pattern of Cdk1/cyclin B activity is piv-
otal for the normal cell cycle and is subject to multiple
control steps [50]. Our approaches, both the global pro-
teomics phospho-antibody array and Western blot analy-
sis of the kinetic changes of the activity status of CDC2/
Cdk1 responding to GH stimulation, have similar and
consistent results. Pre-treatment of MDBK cells with the
AKT inhibitor results in antagonized GH effect and
reduced CDC2/Cdk1 phosphorylation after the GH chal-
lenge, indicating the involvement of CDC2/Cdk1 in the
GH response pathway. The activity of CDC2/Cdk1 is
modulated, directly or indirectly, through the AKT/PKB
pathway.
Another important finding of the present study is that the
AKT inhibitor also induces the prolonged and augmented
activation of Erk1/2, induced by the GH challenge. The
Ras/Raf/MEK/Erk and PI3K/PTEN/AKT signaling cascades
play critical roles in the transmission of signals from
growth factor receptors to regulate gene expression and
prevent apoptosis [51]. The Raf/MEK/Erk kinase cascade is
pivotal in transmitting signals from membrane receptors
to transcription factors that control gene expression, cul-
minating in the regulation of cell cycle progression. This
cascade can prevent cell death through Erk2 and p90
(Rsk) activation and the phosphorylation of apoptotic
and cell cycle regulatory proteins. The PI3K/AKT kinase
cascade also controls apoptosis and can phosphorylate
many apoptotic and cell cycle regulatory proteins. Acti-
vated ERK regulates growth factor-responsive targets in the
cytosol and also translocates to the nucleus where it phos-
phorylates a number of transcription factors that regulate
gene expression. These pathways are interwoven, as AKT
can phosphorylate Raf and result in its inactivation, and
Raf can be required for the antiapoptotic effects of AKT
[52]. The individual effects of activated Raf and AKT on
proliferation, apoptosis and autocrine growth factor syn-
thesis have been studied [52]. Activation of either Raf or
AKT hindered cell death. It has been established that AKT
blocks Erk signaling through the inhibition of Raf1
[53,54]. AKT/PKB can directly phosphorylate Raf1 on
T259, and this can lead to an inhibitory effect of AKT on
the Erk pathway [54]. Our finding reported here indicates
that the ERK signaling pathway is directly involved in the
GH response as reported by many laboratories [16,25,55-
57]. AKT/PKB modulates this response and may exert its
modulating function through crosstalk with the ERK path-
way. Because AKT activation also leads to many down-
stream signals other than eNOS, it is important to further
define the role of crosstalk between the AKT/PKB-eNOS
pathway and other signaling pathways or the elements of
those pathways such as JNK1, TYH, Erb2, elF-4E and
Elf2a. Although this is beyond the immediate scope of the
present research, such a study may reveal that the AKT-
associated modulating of Erk and eNOS phosphorylation
participates in what has been characterized as GH-
induced GH desensitization.
Conclusion
The major conclusions of this study are: We found the
MAP kinase and CDC2 kinase-dependent intracellular
mechanisms are involved in or are the targets of the GH's
action processes. These activities are probably directly or
indirectly modulated by AKT/PKB pathways. We propose
that the AKT/PKB-eNOS module likely functions as a neg-
ative feedback mediator of GH actions.
Methods
Cell culture and treatment
Madin-Darby bovine kidney epithelial cells (MDBK,
American Type Culture Collection, Manassas, VA., and
Catalog No. CCL-22) were cultured in Eagle's minimal
essential medium supplemented with 5% fetal bovine
serum (Invitrogen, Carlsbad, CA) in a 25 cm2 flask with
medium renewal twice per week. Cell cultures were main-
tained in a water-jacked incubator with 5% CO2 at 37°C.
Sub-cultivations were performed when cells attained 80 to
90% confluence, according to the product information
supplied by American Type Culture Collection. Cells were
used for treatment testing at approximately 50% conflu-
ence during the exponential phase of growth. Each exper-
iment was replicated in three independent experiments
with identical conditions unless indicated otherwise.
In vitro GH challenge and modulation of the eNOS/AKT 
axis
Cells were incubated in fresh medium without fetal
bovine serum for about 6 h before the treatments. No BSA
or other protein was added during serum starvation. The
serum-free medium was aspirated from the T-25 flasks
and replaced with the same type of medium containing
the recombinant GH. GH (recombinant bovine GH, Mon-
santo Inc., St. Louis, MO) was added to the culture at 200
ng/ml final concentration. The dose of 200 ng/ml was
chosen based on a previous report [16] and our dose
response experiment on the MDBL cells (data not shown).Journal of Molecular Signaling 2009, 4:1 http://www.jmolecularsignaling.com/content/4/1/1
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For the AKT and eNOS inhibition experiments, 10 μM
AKT inhibitor (Catalog # 124005, CalBiochem, San
Diego, CA.) or eNOS inhibitor (1 mM NG-Monomethyl-
Λ-arginine, CalBiochem) were added to the culture media
30 min before GH treatment. For time course studies, the
activity of cells cultured in T-25 flasks was arrested with
the addition of M-Per® buffer and gentle agitation (Pierce,
Inc., Rockford, IL, as per manufacturer's instructions) at
time '0' (with the addition of fresh serum – GH-free
medium) and at designated time points (as indicated in
each experiments and related figures) after the addition of
GH. As different experimental protocols dictated, dis-
persed cells and contents were sonicated to a uniform
consistency and the protein content was measured by the
traditional Lowry procedure. M-PER is a non-denaturing
detergent-based protein extraction buffer used to extract
total cellular protein quickly. A protease inhibitor cocktail
for use with mammalian cell extracts, and phosphatase
inhibitor cocktails I and II (Sigma, St. Louis, MO), were
added in M-PER immediately before use. For the experi-
ments including a second GH challenge at 75 min, the
medium containing GH was aspirated and replaced with
fresh GH-containing medium. The 75 min samples were
taken immediately after the second GH challenge.
Subcellular extraction and localization of protein from 
MDBK cells
Compartmental localization of the proteins was assessed
by the subcellular fractionation of cultured cells. After
treatment with GH at the indicated time points, proteins
were extracted from MDBK cells using the ProteoExtract®
subcellular extraction kit (Calbiochem), following the
manufacturer's instruction. Stepwise extraction resulted in
the separation of proteins into cytosol, membrane and
nuclear fractions. GAPDH and core histone content were
used as markers for the cytosal and nuclear fractions,
respectively.
Cellular protein separation and Western analysis
Cellular proteins were separated for identification by
standard SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) using 4% to 20% gradient Tris-glycine gels (Invit-
rogen, Carlsbad, CA) under the reducing conditions sug-
gested by the manufacturer. Pre-stained molecular weight
standards (SeeBlue-plus2, Invitrogen) were included. The
separated proteins were eluted from the gels and trans-
ferred to pure nitrocellulose membranes (Protran, 0.2 μm,
Schleicher & Schuell, Dassel, Germany) by semi-moist
electro-transfer. Nonspecific binding of the reagent anti-
bodies to the nitrocellulose matrix was blocked by incu-
bating the membranes with 5% fat-free dry milk in PBS
for 1 h prior to incubation with the antibodies specific to
each desired protein (1:1000 diluted in PBS plus 0.1% Tri-
ton 100). Western blot analyses were performed using
anti-AKT/PKB, anti-phospho-AKT/PKB (Cell Signaling
Technology, Beverly, MA), anti-endothelial NOS (eNOS),
anti-phospho-eNOS (1177phosphoserine-eNOS)
(Upstate Biotech Inc., Lake Placid, NY), anti-CDC2/Cdki1
(Abcam) and p-(Y-15) CDC2/Cdk1(R & D Systems) anti-
bodies. A secondary antibody (Immuno-Pure, anti-
mouse-IgG or anti-rabbit-IgG conjugated with horserad-
ish peroxidase, Pierce Biotechnology, 1:25000 diluted
with PBS) was added and incubated for1 h. Membranes
were washed 5 times with PBS and 0.1% Triton 100.
Immunoblots were exposed to SuperSignal West Pico Sta-
ble Peroxide solution with luminol/enhancer (Pierce Bio-
technology) according to the manufacturer's instructions.
Western blots were then scanned and analyzed using UN-
SCAN-IT software (Silk Scientific, Orem, Utah) to quan-
tify the density of the bands. The quantification was done
with exposures that are in the linear range. Protein gels
were stained with SimpleBlue™ (Invitrogen) to visualize
the proteins and used to normalize the Western blots.
Data were statistically analyzed by ANOVA using Graph-
Pad Prism 5.00 for Windows (GraphPad Software, San
Diego, CA, USA). When significant effects were detected
(P < 0.05), differences between means were estimated by
Tukey's multiple comparison test. Tukey's test is a statisti-
cal test generally used in conjunction with an ANOVA to
find which means are significantly different from one
another. The test compares the means of every treatment
to the means of every other treatment, and identifies
where the difference between two means is greater than
the standard error would be expected to allow. Data are
presented as means +/- SEM.
Functional proteomic analysis
The global proteomics phosphoantibody array-based
approach was performed to analyze the signal transduc-
tion pathways of the GH axis and the roles of AKT/PKB in
MDBK cells utilizing the Kinetworks Phospho-Site Screen
(KPSS)-6.0 (Kinexus Bioinformatics Corporation, Van-
couver, Canada). A wide range of phosphorylation site-
specific antibodies were used in a quantitative fashion as
a specific assay for the regulation of diverse cell signaling
pathways http://www.kinexus.ca/KPSS.htm. KPSS-6.0
was used to screen and quantitate the phosphorylation
status of 33 different phospho-sites from over 150 known
phospho-sites in kinase substrates, in phospho-proteins
with antibodies that recognize specific phosphorylated
epitopes of target proteins. A total of 500 μg of whole cell
lysates from each experimental cell group, control cells
(without GH) and GH treated cells (with or without AKT
inhibitor pre-treatment) was used for each KPSS phos-
phoantibody array screen. This is an antibody-based
method (Kinetworks) that relies on Sodium dodecyl sul-
phate (SDS)-polyacrylamide minigel electrophoresis and
multilane immunoblotters to permit the specific and
quantitative detection of numerous protein kinases or
other signal transduction proteins simultaneously [58].Journal of Molecular Signaling 2009, 4:1 http://www.jmolecularsignaling.com/content/4/1/1
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To further investigate the phosphorylation of the kinases
in the mitogen-activated protein kinase (MAPK) pathway,
we also used the Proteome Profiler Array™-Human Phos-
pho-MAPK Array (R & D Systems, Inc). Sample prepara-
tion, reagent preparation and array protocol followed the
manufacturer's instruction.
List of abbreviations used
AKT/PKB: Protein kinase B; eNOS: endothelial nitric oxide
synthase; CDC2/Cdk1: Cell division control protein 2/
Cyclin-dependent protein kinase 1); GH: growth hor-
mone; JAK2: Janus kinase 2; MDBK: Madin-Darby bovine
kidney epithelial cells; JNK1: cJun NH2 terminal kinase 1;
Erk: extracellular signal-regulated kinases; GSK3a/b: gly-
cogen synthase kinase 3.
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